Statement

Company Vision

We are creating a diagnostic platform that will address the key weaknesses in currently available in-vitro diagnostics and molecular diagnostic technologies. This platform, the Single Particle Interferometric Reflectance Imaging Sensor (SP-IRIS), is based on the detection of single nanoparticles and has demonstrated single virus and single molecule (both protein & nucleic acids) detection in whole blood and serum at clinically relevant levels.

The SP-IRIS platform has the advantage over other diagnostic technologies by allowing clinically relevant detection sensitivity without any complicated sample preparation or signal amplification. Even though other technologies have overcome sample preparation and amplification hurdles, the integration of these sample preparation solutions has made competitor technology more complicated, expensive, and slower. Finally, because SP-IRIS can identify both antibodies and antigens on the same test, a single panel can provide infection and immunological responses.

Over the next five years we will create a diagnostic platform that can be applied to a variety of different biological applications. Some of the applications we are currently working towards are a Viral Hemorrhagic Fever panel (Ebola, Lassa, Marburg) in collaboration with Boston University with support from NIH and an allergy panel with support from CIMIT.

 

Next Generation

Technology

The Single Particle Interferometric Reflectance Imaging Sensor (SP-IRIS) technology, from Nexgen Arrays, allows detection of biomolecules with single target (virus/protein/molecule) resolution.  The SP-IRIS technology uses a substrate where tens of targets can be monitored in one test.  The substrate is contained inside a cartridge that runs the test and can be scanned using the SP-IRIS imager. Possible applications include biosurveillance, pharmaceutical,  diagnostics,  and environmental monitoring.

The SP-IRIS imager is able to count individual nanoparticles (e.g. virus), as small as 60 nm, on the sensor surface using a capture probe, without amplification.  For smaller particles, (e.g. genes, proteins) nanoparticle tags can be used to count single biomolecules.

Multiple targets on a single substrate

 

Up to 10s of targets can be detected

Direct detection from complex fluids

 

Blood, serum, and other biological fluids

Label-free Detection

 

Non-metallic nanoparticle detection (60 nm – 200 nm), Viruses, synthetic particles, and other nanoparticles can be accurately sized

Single-Particle Detection of Small Molecules

 

Proteins, Nucleic Acids, and toxins can be detected using metallic nanoparticles

Advanced

Hardware

spa1001-instrument-transparent
For clinical diagnostics, “Time is life”. This was a powerful quote that we listened to during our interviews with clinical lab directors around the country. This quote succinctly conveyed a recurring theme we heard from diagnostic lab directors regarding the need to rapidly identify and cohort various infectious pathogens in the medium and large hospital setting, especially at pediatric hospitals.

We identified the need for rapid multiplexed and sensitive diagnostics that can be used by novice users. Currently, hospitals will run rapid tests even though they provide poor sensitivity and specificity and in parallel run a more sensitive laboratory based test to confirm initial diagnosis made by the clinician. Having more accurate rapid tests will allow accurate treatment and triage of patients which will result in better patient care and lower hospital costs. Our platform, can disrupt the current rapid diagnostic test paradigm because it’s ultra-sensitive, multiplexed, and can be run in a sample-to-answer format.

Fully Automated

 

Sample-to-answer system enables repeatable results

Multiplexed Detection

 

Identify a specific pathogen from a panel of similar pathogens

Rapid Results

 

Sample-to-answer in one hour or less

Faster Treatment

 

Rapid results can enable better treatment options

Rapid Detection of

Viral Hemorrhagic Fevers

VHF-BROCHURE

In collaboration with Boston University, we are developing a solid-phase assay for direct detection of a number of VHF pathogans. The SP-VHF-03 panel can detect and distinguish an infection from three VHF pathogens that all share common symptoms.

Did you know? Lassa Fever is an endemic virus in West Africa that has identical symptoms to Ebola Fever. Until the West-African Ebola Outbreak of 2014, Lassa Fever has killed more people every year than the total recorded history of Ebola Fever Outbreaks.

Take A Look

Recent Works

About

Our Team

Nexgen Arrays

News Update

Medgadget Reports on the SP-IRIS platform and highlights recent prototypes from Nexgen Arrays

http://www.medgadget.com/2014/10/rapid-ebola-detector-identifies-infected-patients-in-about-an-hour.html Editors at Medgadget accurately discuss the capabilities and results for the SP-IRIS platform, with a focus on recent VSV-EBOV results. Medgadget: Rapid Ebola Detector Identifies Infected Patients in About an Hour

IBTimes highlights Cheap and Quick Diagnose of Ebola via Nanotechnology

http://www.ibtimes.co.uk/ebola-outbreak-how-nanotechnology-can-cheaply-quickly-diagnose-deadly-virus-1468265 Lydia Smith at the International Business Times highlights claims that Ebola diagnostics can be accomplished cheaply and quickly via nanotechnology developed at Boston University and Nexgen IBTimes UK: Ebola Outbreak- How Nanotechnology Can ‘Cheaply and Quickly’ Diagnose the Deadly Virus  

Computerworld features Ebola detection technology developed by Professor John Connor and Nexgen Arrays

http://www.computerworld.com/article/2690772/researchers-hope-to-diagnose-deadly-ebola-virus-with-nanotech.html Sharon Gaudin at Computerworld discusses how nanotechnology is being used for the rapid diagnosis of Ebola, with technology co-developed by NexGen Arrays. Computerworld: Researchers hope to diagnose deadly Ebola virus with nanotech

BU Today Features Ebola Detection Technology Developed with NexGen Arrays

http://www.bu.edu/today/2014/containing-ebola-with-nanotechnology/ The daily BU periodical highlights the research done at Boston University by Professor John Connor and Professor Selim Unlu. David Freedman’s latest prototype instrument, developed at Nexgen Arrays, is featured in the article. BU Today: Containing Ebola with Nanotechnology

Want to Know More?

Contact Us